Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 19, 2018
Event: Receipt of FDA acknowledgement for a New Drug Application (NDA) resubmission.
Key Financial Metrics
This filing is a current report regarding a regulatory event and does not contain financial statements. The text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Regulatory Status
- NDA Acknowledgement: The FDA acknowledged receipt of the NDA for DEXTENZA (dexamethasone insert) 0.4mg on July 19, 2018.
- Indication: Treatment of ocular pain following ophthalmic surgery.
- Classification: The FDA considers this a Class 2 response to the July 2017 Complete Response Letter.
- Target Date: The Prescription Drug User Fee Act (PDUFA) target date for the completion of the FDA review is December 28, 2018.
Outlook, Risks, and Management Commentary
Forward-Looking Statements: The filing includes extensive forward-looking statements regarding the development of DEXTENZA and other pipeline candidates (OTX-TP, OTX-TIC, OTX-TKI, OTX-IVT), the collaboration with Regeneron Pharmaceuticals, and the sufficiency of cash resources.
Risks and Uncertainties: Management highlights substantial risks that could cause actual results to differ from expectations, including:
- Timing and costs of commercialization.
- Initiation and conduct of clinical trials.
- Regulatory submission outcomes and approvals.
- Scientific approach and development progress.
- Sufficiency of cash resources and potential need for additional financing.
- Outcomes of ongoing legal proceedings.
Investor Verification Checklist
- Verify the PDUFA target date of December 28, 2018, for the DEXTENZA NDA review completion.
- Confirm the specific manufacturing deficiencies addressed in the Class 2 response to the July 2017 Complete Response Letter.
- Review the most recent quarterly or annual report for current cash resources and burn rate, as this 8-K does not provide liquidity data.
- Monitor the status of the collaboration with Regeneron Pharmaceuticals for potential future payments.
- Check for updates on other pipeline candidates (OTX-TP, OTX-TIC, OTX-TKI, OTX-IVT) mentioned in the forward-looking statements.